UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $39.77 Million Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 8.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 880,199 shares of the company's stock after selling 81,038 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.50% of Twist Bioscience worth $39,767,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of TWST. Thrivent Financial for Lutherans bought a new stake in Twist Bioscience in the third quarter valued at approximately $43,992,000. Point72 Asset Management L.P. increased its position in shares of Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company's stock valued at $33,168,000 after buying an additional 613,057 shares in the last quarter. Fred Alger Management LLC raised its stake in Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company's stock worth $32,272,000 after buying an additional 575,080 shares during the period. Victory Capital Management Inc. lifted its holdings in Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company's stock worth $15,187,000 after acquiring an additional 300,891 shares in the last quarter. Finally, Farallon Capital Management LLC acquired a new position in Twist Bioscience in the second quarter valued at about $9,462,000.

Twist Bioscience Trading Up 3.3 %

NASDAQ:TWST traded up $1.68 on Wednesday, hitting $52.29. 550,484 shares of the company's stock were exchanged, compared to its average volume of 944,701. The firm has a 50-day moving average price of $44.02 and a 200-day moving average price of $46.27. Twist Bioscience Co. has a 52 week low of $24.25 and a 52 week high of $60.90.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. TD Cowen reaffirmed a "buy" rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. Evercore ISI increased their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Scotiabank boosted their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a research report on Tuesday, November 19th. Finally, Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and an average price target of $51.00.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 1,730 shares of the company's stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the sale, the chief executive officer now directly owns 495,523 shares of the company's stock, valued at approximately $23,259,849.62. This represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Chess sold 3,600 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00. Following the completion of the sale, the director now owns 21,641 shares of the company's stock, valued at $1,022,753.66. This trade represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 98,118 shares of company stock worth $4,391,151. Corporate insiders own 3.92% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.